Optomed Oyj
Senaste sammanfattade pressmeddelande från Optomed Oyj
Threads
Optomed Plc announced on 9 August 2024 that it has conveyed 8,744 treasury shares to its Board of Directors as part of their annual remuneration, based on the decision of the Annual General Meeting 2024. Additionally, a total of 310,500 shares have been subscribed under the company’s stock option plans from 2015, 2017, 2018C, and 2019B, with treasury shares used for these subscriptions. As a result, the total number of treasury shares now stands at 34,729. Optomed is a Finnish medical technology company specializing in handheld fundus cameras and software aimed at diagnosing eye diseases like diabetic retinopathy, with operations in over 60 countries. For further information, contact CFO Sakari Knuutti at sakari.knuutti@optomed.com.
Optomed Plc announced a manager's transaction involving Seppo Mäkinen, a member of the board. On August 9, 2024, Mäkinen received 1,249 shares as part of a share-based incentive, with a unit price of 0.00 EUR. The transaction was reported as an initial notification.
Optomed Plc reported a manager's transaction on August 9, 2024, involving Ty Lee, a member of the Board. Lee received a share-based incentive consisting of 1,249 shares, with no associated cost. The transaction was classified as an initial notification.
On August 9, 2024, at 18:30 EET, Optomed Plc reported a manager's transaction involving Petri Salonen, a member of the Board/Deputy member. The transaction, which was an initial notification, involved the receipt of a share-based incentive. The transaction date was August 9, 2024, and the instrument type was a share with ISIN FI4000410881. The transaction involved 2499 shares at a unit price of 0.00 EUR, resulting in a volume-weighted average price of 0.00 EUR.